PortfoliosLab logoPortfoliosLab logo
IMVT vs. AXSM
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

IMVT vs. AXSM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Immunovant, Inc. (IMVT) and Axsome Therapeutics, Inc. (AXSM). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, IMVT achieves a 51.93% return, which is significantly higher than AXSM's 19.36% return.


IMVT

1D
-2.18%
1M
-0.44%
6M
48.54%
YTD
51.93%
1Y
145.83%
3Y*
18.74%
5Y*
29.85%
10Y*
ALL TIME*
16.27%

AXSM

1D
-7.10%
1M
-10.77%
6M
18.31%
YTD
19.36%
1Y
111.60%
3Y*
41.26%
5Y*
35.01%
10Y*
39.83%
ALL TIME*
34.71%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$153.10M$171.36M$209.26M
$35.51M$39.13M$60.17M

IMVT vs. AXSM - Yearly Performance Comparison


2026 (YTD)2025202420232022202120202019
IMVT
Immunovant, Inc.
51.93%2.62%-41.21%137.35%108.33%-81.55%191.05%11.37%
AXSM
Axsome Therapeutics, Inc.
19.36%115.86%6.31%3.19%104.16%-53.63%-21.18%15.40%

Correlation

The correlation between IMVT and AXSM is 0.39, which is low. Their historical price movements had little consistent relationship.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.39

Correlation (3Y)
Balances recent behavior with more history.

0.40

Correlation (5Y)
Shows whether the relationship held over a longer period.

0.37

Correlation (All Time)
Calculated using the full available price history since Dec 19, 2019

0.36

Fundamentals

Market Cap

IMVT:

$7.93B

AXSM:

$11.22B

EPS

IMVT:

-$2.71

AXSM:

-$3.72

PB Ratio

IMVT:

9.23

AXSM:

204.46

Total Revenue (TTM)

IMVT:

$0.00

AXSM:

$708.24M

Gross Profit (TTM)

IMVT:

-$206.00K

AXSM:

$655.82M

EBITDA (TTM)

IMVT:

-$527.21M

AXSM:

-$172.72M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

IMVT vs. AXSM — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

IMVT
IMVT Risk / Return Rank: 9696
Overall Rank
IMVT Sharpe Ratio Rank: 9494
Sharpe Ratio Rank
IMVT Sortino Ratio Rank: 9696
Sortino Ratio Rank
IMVT Omega Ratio Rank: 9292
Omega Ratio Rank
IMVT Calmar Ratio Rank: 9898
Calmar Ratio Rank
IMVT Martin Ratio Rank: 9898
Martin Ratio Rank

AXSM
AXSM Risk / Return Rank: 9696
Overall Rank
AXSM Sharpe Ratio Rank: 9696
Sharpe Ratio Rank
AXSM Sortino Ratio Rank: 9797
Sortino Ratio Rank
AXSM Omega Ratio Rank: 9595
Omega Ratio Rank
AXSM Calmar Ratio Rank: 9797
Calmar Ratio Rank
AXSM Martin Ratio Rank: 9797
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

IMVT vs. AXSM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Immunovant, Inc. (IMVT) and Axsome Therapeutics, Inc. (AXSM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


IMVTAXSMDifference
Sharpe ratioReturn per unit of total volatility

-0.41

Sortino ratioReturn per unit of downside risk

-0.27

Omega ratioGain probability vs. loss probability

1.40

1.47

-0.07

Calmar ratioReturn relative to maximum drawdown

8.20

6.25

+1.95

Martin ratioReturn relative to average drawdown

21.37

18.02

+3.35

IMVT vs. AXSM - Sharpe Ratio Comparison

The current IMVT Sharpe Ratio is 2.29, which is comparable to the AXSM Sharpe Ratio of 2.69. The chart below compares the historical Sharpe Ratios of IMVT and AXSM, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

IMVT vs. AXSM - Drawdown Comparison

The maximum IMVT drawdown since its inception was -93.59%, which is greater than AXSM's maximum drawdown of -86.65%. Use the drawdown chart below to compare losses from any high point for IMVT and AXSM.


Loading charts...

Drawdown Indicators


IMVTAXSMDifference

Max Drawdown

Largest peak-to-trough decline

-93.59%

-86.65%

-6.94%

Max Drawdown (1Y)

Largest decline over 1 year

-17.19%

-18.50%

+1.31%

Max Drawdown (3Y)

Largest decline over 3 years

-69.88%

-32.69%

-37.19%

Max Drawdown (5Y)

Largest decline over 5 years

-69.88%

-61.08%

-8.80%

Max Drawdown (10Y)

Largest decline over 10 years

-81.26%

Current Drawdown

Current decline from peak

-26.73%

-14.57%

-12.16%

Average Drawdown

Average peak-to-trough decline

-53.37%

-39.06%

-14.31%

Ulcer Index

Depth and duration of drawdowns from previous peaks

6.59%

6.41%

+0.18%

Volatility

IMVT vs. AXSM - Volatility Comparison

The current volatility for Immunovant, Inc. (IMVT) is 9.73%, while Axsome Therapeutics, Inc. (AXSM) has a volatility of 14.94%. This indicates that IMVT experiences smaller price fluctuations and is considered to be less risky than AXSM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


IMVTAXSMDifference

Volatility (1M)

Calculated over the trailing 1-month period

9.73%

14.94%

-5.21%

Volatility (6M)

Calculated over the trailing 6-month period

44.56%

28.72%

+15.84%

Volatility (1Y)

Calculated over the trailing 1-year period

61.81%

42.96%

+18.85%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

74.72%

70.11%

+4.61%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

77.70%

90.38%

-12.68%

Dividends

IMVT vs. AXSM - Dividend Comparison

Neither IMVT nor AXSM has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

IMVT vs. AXSM - Financials Comparison

This section allows you to compare key financial metrics between Immunovant, Inc. and Axsome Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

Frequently Asked Questions


IMVT and AXSM have a correlation of 0.39, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

AXSM has higher volatility (14.94%) compared to IMVT (9.73%). In terms of maximum drawdown, IMVT dropped -93.59% vs AXSM's -86.65%.

AXSM currently has the higher Sharpe Ratio (2.69 vs 2.29), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for IMVT and AXSM

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer